Business Wire

Scientist.com and Brain and Spine Institute’s Bioincubator, iPEPS, Launch Biotech Startup Competition for Companies Accelerating CNS Disease Research

Del

Scientist.com, the life science industry’s leading online marketplace for outsourced research, and The Brain and Spine Institute incubator, iPEPS-ICM, the first innovation accelerator dedicated to brain diseases in France, are partnering to launch a call for biotech startups developing novel approaches to fighting CNS diseases as part of a pitch competition.

This startup call is aimed at helping young biotech entrepreneurs to fast track the development of their innovative projects in one of the most thriving research and innovation ecosystems in Europe. This competition is open to biotech startups worldwide in existence for less than two years developing a novel therapeutic and/or diagnostic approach with a main focus on central nervous system diseases (neuro-oncology, psychiatry, neurological disorders or preventive health).

“In the field of diseases of the nervous system, the probability that drug candidates reach the market is only 7%, compared with an average of 15%,” stated Julien Elric, iPEPS incubator manager. “This outcome makes it very difficult for young enterprises to establish themselves in biotechnology. This startup competition is here to help young entrepreneurs to develop their innovation in the best environment, with 700 researchers at The Brain and Spine Institute, 25 state-of-the-art platforms, a LivingLab and a FabLab.”

Applications can be submitted from May 28, 2018 through July 16, 2018 at ipeps.icm-institute.org/startupcall. An expert panel of judges will narrow the applicant field to 12 in its initial round of selections in early September. A second round of selections occurring in mid-September will determine the winner and one runner up. The winner will have the opportunity to pitch the project to an audience of investors and experts at an event scheduled for late September.

The grand prize winner receives 6 months free rent at iPEPS’ state-of-the-art facilities located in Paris’ 13th district, including consulting with experts in preclinical/clinical development as well as $10K in research services provided through the Scientist.com marketplace. One runner up will receive 3 months free rent at iPEPS and $6K in research services through the Scientist.com marketplace.

“Neurological disorders affect almost a billion people globally,” commented Dan Kagan, PhD, COO of Scientist.com. “This science-based competition highlights novel approaches to these types of diseases and provides two early-stage companies the opportunity to take the next step in the development of their innovative ideas.”

About Scientist.com

Scientist.com is the world's leading marketplace for outsourced research. The marketplace simplifies the entire research sourcing process, saving time and money and providing access to the latest innovative tools and technologies while maintaining full compliance with an organization’s procurement policies. Scientist.com operates private enterprise marketplaces for most of the world’s major pharmaceutical companies, VWR and the US National Institutes of Health (NIH). Since its founding in 2007, Scientist.com has raised more than $33 million from Leerink Transformation Partners, 5AM Ventures, Heritage Provider Network, Bootstrap Ventures and Hollywood producer Jack Giarraputo, among others. Visit scientist.com to learn more.

Join Scientist.com on social media: YouTube, LinkedIn, Twitter, Facebook, Google+ and Instagram.

About The Brain and Spine Institute

Located in the heart of the Pitié-Salpêtrière University Hospital Center, the first neurology hospital in France, The Brain and Spine Institute (ICM) is a strong link between basic research and the clinical world. The Institute consists of over 700 researchers and clinicians, 17 cutting-edge technological platforms and a 1000m² office space intended for incubation of startups. The objective is to produce ambitious research by combining scientific creativity and therapeutic purpose.

Contact information

Media Contact:
Scientist.com
Sean Preci
Director of Communications
+1 858-455-1300, ext. 401
marketing@scientist.com
or
For further information, please contact:
The Brain and Spine Institute
Axelle de Chaillé
axelle.dechaille@icm-institute.org
+33 (0)1.57.27.47.02 / +33 (0)7.63.31.55.96
or
Mathilde Gratiot
mathilde.gratiot@icm-institute.org
+ 33 (0)1.57.27.41.87

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Hilton Launches New Brand, Signia Hilton, Delivering Sophisticated Travel While Reimagining Meetings and Events22.2.2019 17:00:00Pressemelding

Hilton (NYSE: HLT) today announced the launch of Signia Hilton, its dynamic, new meetings-and-events-focused brand. The portfolio of hotels is setting out to transform the industry for meeting professionals and sophisticated business travelers by infusing state-of-the-art technology and design into every aspect of the guest experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190222005071/en/ The brand further reinforces Hilton’s commitment to innovation that meets the evolving needs of today’s travelers and will bring premium experiences to top urban and resort destinations around the world. “In our 100th year of hospitality, we are more focused than ever on providing exceptional experiences to all of our guests – and that includes evolving those experiences to meet their changing needs,” said Christopher J. Nassetta, president and CEO, Hilton. “We are proud to launch Signia Hilton, which exemplifies our innovative sp

Axonics® Granted Expanded CE Mark Label; First and Only Sacral Neuromodulation System Approved for Use with Full-Body MRI Scans22.2.2019 16:30:00Pressemelding

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, announced today that it has received CE mark approval for 1.5T and 3T full-body magnetic resonance imaging (“MRI”) conditional labeling for the Axonics r-SNM® System. The Axonics r-SNM System is the only implantable SNM system that has received full-body MRI conditional labeling for sale in Europe1. Raymond W. Cohen, Chief Executive Officer of Axonics, said, “Without this labeling, any patient requiring an MRI scan on any body part below the head must have their neurostimulator surgically explanted prior to the MRI scan, resulting in an additional surgery for the patient and additional costs to patients and the healthcare system. This authorization of full-body MRI scans in Europe is another important milestone for Axonics, differentiating our te

Fantastec Joins Forces with Arsenal FC Launching Official Blockchain Collectibles App22.2.2019 14:30:00Pressemelding

Fantastec announced today its first football licensing agreement with Premier League club Arsenal FC for a new blockchain authenticated collectibles app called Fantastec SWAP. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190222005277/en/ Arsenal players appear on Fantastec SWAP in official licensing deal (Graphic: Business Wire) London-based Fantastec is a leading sports fan technology innovator, and its blockchain based ‘SWAP’ app will have broad appeal to global sports fans, gamers and sports card collectors alike. Fantastec SWAP unlocks unique and authentic club content through the app, like player autographs and exclusive footage. With its innovative blockchain technology, fans around the world can now discover, collect and swap officially licensed club collectibles with other fans with complete trust. “Fantastec SWAP is a game-changer for international football fans as well the sports collectibles industry,” commented

Volkswagen Protects Virtual Key Sharing App with Trustonic Application Protection22.2.2019 13:42:00Pressemelding

Volkswagen is working with mobile cyber security leader Trustonic to enable customers to use smartphones to access their vehicles, and to securely share their digital car keys to grant access to others via a smartphone app. Volkswagen is using the Trustonic Application Protection (TAP) platform to secure the mobile app and ensure that sensitive information and key transfer requests are securely displayed to, and approved by, a real authenticated user on a trusted device and not by hackers or malware simulating a user or device. “The smartphone is becoming the vehicle key of the future and our We Connect service is the interface for this today in the new Volkswagen Passat,” comments Alf Pollex, Head of Infotainment and Connected Car at Volkswagen AG. “The user installs the We Connect app on their smartphone which is then authorized via the infotainment system with a Transaction Number. The Mobile Key will be compatible with Android-based Samsung devices. No mobile network connection is

Mundipharma EDO GmbH: US FDA grants Orphan Drug Designation for etoposide toniribate in relapsed/refractory biliary tract cancer22.2.2019 13:30:00Pressemelding

Mundipharma EDO GmbH, part of the Mundipharma network of independent associated companies, and Imbrium Therapeutics L.P., an operating subsidiary of Purdue Pharma L.P., today announced that the US FDA has granted Orphan Drug Designation (ODD) to etoposide toniribate for the treatment of relapsed/refractory biliary tract cancer, also known as cholangiocarcinoma.3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190222005126/en/ Biliary tract cancer is a rare tumour with approximately 8,000 patients diagnosed in the US every year and 10,571 in Europe.4,5 The FDA grants ODD status to medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US. Radical surgery is the only curative treatment for biliary tract cancer but, in most cases, the cancer is inoperable. Patients who fail first-line chemotherapy have limited treatment options and the standard of

Lenovo Data Center Group Delivers Broad Edge Computing Portfolio, Expands Investments in IoT22.2.2019 13:13:00Pressemelding

Next week at MWC Barcelona, Lenovo Data Center Group (DCG) will showcase continued investments in its solutions supporting IoT and edge computing as part of its IoT growth plan over the next few years. Building on the momentum of its fifth consecutive quarter of profit growth, Lenovo DCG is building a portfolio that takes infrastructure to where the data is, whether that be in the traditional data center, in the cloud or increasingly, at the edge. Today, around 10 percent of enterprise-generated data is created and processed outside a traditional centralized data center or cloud. By 2022, Gartner predicts this figure will reach 75 percent. This migration is driving increased concerns around data privacy, security and regulations coupled with challenges of latency, bandwidth and downtime. Lenovo is addressing these challenges by creating a broad portfolio of edge computing offerings that address the different ways that customers want to deploy edge computing solutions for IoT use cases.